Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching Efavirenz to Dolutegravir in HIV Patients with CNS Toxicity
NCT02285374Phase 4Unknown
- Sponsor
- St Stephen's AIDS Trust
- Start
- Nov 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dolutegravir in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by St Stephen's AIDS Trust. Primary endpoint: Rate of neuropsychiatric and central nervous system (CNS) toxicity at 4 weeks. Status: unknown.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02285374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02285374.